Author:
Bose Sourav K.,Kennedy Kara,Peranteau William H.
Abstract
Purpose of review
The development of modern gene editing tools alongside promising innovations in gene sequencing and prenatal diagnostics as well as a shifting regulatory climate around targeted therapeutics offer an opportunity to address monogenic diseases prior to the onset of pathology. In this review, we seek to highlight recent progress in preclinical studies evaluating the potential in-utero gene editing as a treatment for monogenic diseases that cause morbidity or mortality before or shortly after birth.
Recent findings
There has been significant recent progress in clinical trials for postnatal gene editing. Corresponding advances have been made with respect to in-utero cell and enzyme replacement therapies. These precedents establish the foundation for ‘one-shot’ treatments by way in-utero gene editing. Compelling preclinical data in liver, pulmonary and multisystemic diseases demonstrate the potential benefits of in-utero editing approaches.
Summary
Recent proof-of-concept studies have demonstrated the safety and feasibility of in-utero gene editing across multiple organ systems and in numerous diseases. Clinical translation will require continued evolution of vectors and editing approaches to maximize efficiency and minimize unwanted treatment effects.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Obstetrics and Gynecology
Reference24 articles.
1. National Center on Birth Defects and Developmental Disabilities [Internet];Centers for Disease Control and Prevention,2022
2. In utero gene therapy: progress and challenges;Bose;Trends Mol Med,2021
3. Cytokine responses to adenovirus and adenovirus vectors;Atasheva;Viruses,2022
4. The CRISPR/Cas Tool Kit for Genome Editing [Internet],2022
5. In utero gene editing for inherited lung diseases;White;Curr Stem Cell Rep,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献